News
In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and ...
Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback